Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Endoskopisk Sleeve Gastroplastik (ESG) Prospektiv Studie för Fetma (EGO-Studien)

3 november 2026 uppdaterad av: IHU Strasbourg

Prospektiv studie av endoskopisk sleeve gastroplasti (ESG) för fetma

EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions

The project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.

Studieöversikt

Status

Rekrytering

Betingelser

Detaljerad beskrivning

Obesity, particularly morbid obesity, is a major public health issue in France. According to the latest data from the ObÉpi-Roche 2020 survey, more than 17% of French adults are obese. Obesity is a well-established risk factor for many chronic diseases such as type 2 diabetes, cardiovascular disease, high blood pressure (HBP), musculoskeletal disorders, certain cancers, and non-alcoholic steatohepatitis (NASH). It is associated with a significant reduction in life expectancy and represents a direct cost estimated at more than €5 billion per year for the French healthcare system.

While bariatric surgery (particularly sleeve gastrectomy and gastric bypass) remains the gold standard treatment for severe obesity, it is invasive, costly, and only offered to a minority of patients (less than 10% of eligible patients). In addition, certain medical contraindications, refusal of surgery, and waiting times limit access to this treatment.

Endoscopic sleeve gastroplasty ("Endosleeve"). Endoscopic sleeve gastroplasty (ESG) is an innovative, non-surgical, natural procedure that reduces stomach volume without resection or anastomosis. It has shown promising results in terms of weight loss, metabolic improvement, and safety, while being reversible and reproducible. The MERIT randomized controlled trial in USA (JAMA, 2022) demonstrated an average weight loss of 13.6% of total body weight at 12 months (vs. 0.8% in the control group), as well as a significant improvement in comorbidities such as type 2 diabetes and hypertension.

Hypothesis and objective of the study The hypothesis of this study is that ESG, when performed under routine care conditions in the United States, leads to significant and sustainable weight loss, associated with an improvement in comorbidities, with a favorable safety profile. The main objective of this project is therefore to evaluate, on a national scale, the clinical efficacy, safety, and procedural variability of ESG through a multicenter real-world cohort.

To date, no large-scale French study has analyzed the results of ESG in real-world settings. This hinders its integration into national healthcare pathways, its reimbursement by the French national health insurance system, and its wider adoption by the medical community. The question raised-the rigorous evaluation of ESG in the French context-therefore remains unanswered.

This project aims to generate robust data representative of the national clinical reality in order to support the supervised development of ESG. Expected outcomes include the publication of scientific articles in peer-reviewed journals, the presentation of results at international conferences, contributions to health technology assessment work, and the establishment of a national registry of endoscopic gastroplasty. This work could represent a major advance in the therapeutic arsenal for obesity, supporting the integration of ESG as a recognized, validated, and reimbursed option in French healthcare pathways.

Studietyp

Observationell

Inskrivning (Beräknad)

300

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • Aix-en-Provence, Frankrike
        • Rekrytering
        • Hôpital Privé de Provence
        • Kontakt:
      • Besançon, Frankrike
        • Har inte rekryterat ännu
        • Polyclinique de Franche-Comté
        • Kontakt:
      • Lille, Frankrike
      • Lyon, Frankrike
      • Lyon, Frankrike
        • Rekrytering
        • Hospices Civils de Lyon - Hôpital Edourard HERRIOT
        • Kontakt:
      • Montpellier, Frankrike
        • Har inte rekryterat ännu
        • Clinique Clémentville
        • Kontakt:
      • Saint-Etienne, Frankrike
        • Har inte rekryterat ännu
        • Centre Mutualiste de l'Obésité
        • Kontakt:
      • Saint-Grégoire, Frankrike
        • Har inte rekryterat ännu
        • CHP Saint-Grégoire
        • Kontakt:
      • Strasbourg, Frankrike
        • Rekrytering
        • Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil
        • Kontakt:
      • Sète, Frankrike
        • Rekrytering
        • Polyclinique Sainte Thérèse
        • Kontakt:
      • Échirolles, Frankrike
      • Baie-Mahault, Guadeloupe
        • Har inte rekryterat ännu
        • Clinique les Eaux Claires
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Adult patients with obesity scheduled for endoscopic gastroplasty

Beskrivning

Inclusion Criteria:

  • Patients aged 18 to 75 years.
  • Patients with a Body Mass Index (BMI) ≥ 30 kg/m².
  • Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy).
  • Patients not eligible for bariatric surgery or does not wish to undergo it.
  • Patients who can undergo general anesthesia.
  • Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study.
  • Patients who are able to fully understand the study and are willing to give their consent to participate in the study.
  • Patients affiliated with the French social security system.

Exclusion Criteria:

  • Patients with contraindications to endoscopic gastroplasty
  • Patients with active peptic ulcer disease or significant gastroparesis
  • Patients with a history of bariatric, gastric, or esophageal surgery.
  • Patients who have started medication in the last 3 months that is known to cause weight gain.
  • Patients with a history of uncontrolled, poorly controlled, or suspected eating disorders or psychiatric illness.
  • Patients with unstable and precarious health, as determined and assessed by the investigator.
  • Patients who are pregnant, breastfeeding, or of childbearing age and not using effective contraception.
  • Patients who are currently excluded (as determined by a previous or ongoing study).
  • Patients under judicial protection.
  • Patients under guardianship, conservatorship or subject to any form of protective supervision

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: CASE_ONLY
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Alla vuxna patienter med fetma som är schemalagda för endoskopisk gastroplasti (ESG)

Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device which allows for a reduction in stomach volume without resection or anastomosis

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Total Body Weight Loss
Tidsram: At the inclusion and 24 months after procedure

Assessment of weight loss in terms of total body weight loss (TBWL, %) 24 months after surgery

At the inclusion and 24 months after procedure

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Excess weight loss
Tidsram: At the inclusion and 24 months after procedure

Assessment of weight loss in terms of excess weight loss (EWL, %) at 24 months post-procedure

At the inclusion and 24 months after procedure
Body Mass Index (BMI)
Tidsram: From ESG procedure to the end of participation at 24 months post-procedure

Assessment of weight loss in terms of change in Body Mass Index (BMI) at 24 months post-procedure

From ESG procedure to the end of participation at 24 months post-procedure
Adverse events
Tidsram: From ESG procedure to the end of participation at 24 months post-procedure

Rate of minor and major adverse events (e.g., perforation, delayed gastric emptying, reflux symptoms) throughout follow-up for up to 24 months post-procedure

From ESG procedure to the end of participation at 24 months post-procedure
Comorbidities improvement
Tidsram: From ESG procedure to the end of participation at 24 months post-procedure

Assessment of improvement in comorbidities (type 2 diabetes, hypertension, dyslipidemia, sleep apnea) and obesity-related complications over 24 months using the SF-BARI (Swiss-Finnish BARIatric metabolic outcome score) questionnaire: a score developed to evaluate treatment outcomes in obesity management

From ESG procedure to the end of participation at 24 months post-procedure
Quality of life improvement
Tidsram: From ESG procedure to the end of participation at 24 months post-procedure

Assessment of quality of life over 24 months using the GIQLI (Gastrointestinal Quality of Life Index) questionnaire: digestive quality of life score comprising 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments

From ESG procedure to the end of participation at 24 months post-procedure
Additional treatments
Tidsram: From ESG procedure to the end of participation at 24 months post-procedure

Compilation of additional treatments or revisions required after the procedure

From ESG procedure to the end of participation at 24 months post-procedure

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Huvudutredare: Silvana PERRETTA, MD-PhD, Hôpitaux Universitaires de Strasbourg

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

17 mars 2026

Primärt slutförande (Beräknad)

1 mars 2030

Avslutad studie (Beräknad)

1 mars 2030

Studieregistreringsdatum

Först inskickad

27 februari 2026

Först inskickad som uppfyllde QC-kriterierna

27 februari 2026

Första postat (Faktisk)

4 mars 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera